Scancell Holdings (FRA:SCP) Inventories, Inventories Adjustments : €0.00 Mil (As of Oct. 2023)

View and export this data going back to 2013. Start your Free Trial

What is Scancell Holdings Inventories, Inventories Adjustments?

Scancell Holdings's Inventories, Inventories Adjustments for the quarter that ended in Oct. 2023 was €0.00 Mil.

Scancell Holdings Inventories, Inventories Adjustments Historical Data

The historical data trend for Scancell Holdings's Inventories, Inventories Adjustments can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Scancell Holdings Inventories, Inventories Adjustments Chart

Scancell Holdings Annual Data

Trend

Apr14

Apr15

Apr16

Apr17

Apr18

Apr19

Apr20

Apr21

Apr22

Apr23

Inventories, Inventories Adjustments

Get a 7-Day Free Trial

Scancell Holdings Semi-Annual Data
	Apr14	Oct14	Apr15	Oct15	Apr16	Oct16	Apr17	Oct17	Apr18	Oct18	Apr19	Oct19	Apr20	Oct20	Apr21	Oct21	Apr22	Oct22	Apr23	Oct23
Inventories, Inventories Adjustments	Get a 7-Day Free Trial															-	-	-	-	-

Scancell Holdings Inventories, Inventories Adjustments Calculation

Inventories, Inventories Adjustments represents certain charges made in the current period in inventory resulting from breakage, spoilage, employee theft and shoplifting, etc.

Scancell Holdings (FRA:SCP) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Scancell Holdings PLC (FRA:SCP) » Definitions » Inventories, Inventories Adjustments

Comparable Companies

Traded in Other Exchanges

SCLP.GB:UK SCLP:UK

Address

Sanders Road, Unit 202, Bellhouse Building, Oxford Science Park, Oxford, GBR, OX4 4GD

Website

https://www.scancell.co.uk

Scancell Holdings PLC is engaged in the discovery and development of novel vaccines for the treatment of cancer. The company is exploiting the unrivalled potential of the immune system to seek out and destroy cancer using two proprietary immuno-oncology platforms: ImmunoBody and Moditope. Its potent innovative DNA-based ImmunoBody therapies generate ultra-high avidity T cell responses that target and eliminate cancerous tumors. Its Moditope platform technology overcomes the immune suppression induced by tumors themselves, allowing activated T cells to seek out and kill tumor cells that would otherwise be hidden from the immune system.

Scancell Holdings (FRA:SCP) Headlines

No Headlines